Agenus | AGEN - Selling And Administration Expenses


Agenus reported $23.6M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Agenus USD 23.6M 448K Sep/2025
Amgen USD 1.94B 237M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Celldex Therapeutics USD 6.63M 546K Sep/2025
CSL USD 727M 453M Jun/2025
Dynavax Technologies USD 40.09M 1.45M Sep/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Glaxosmithkline GBP 2.91B 817.89M Sep/2025
Incyte USD 390.41M 61.33M Dec/2025
Intrexon USD 10.31M 41K Jun/2024
J&J USD 6.75B 831M Dec/2025
Jiangsu Hengrui CNY 3.23B 111.82M Sep/2025
Karyopharm Therapeutics USD 27.19M 442K Dec/2024
MacroGenics USD 9.9M 600K Sep/2025
Merck EUR 1.46B 16M Sep/2025
Merck USD 2.85B 215M Dec/2025
Novartis USD 3.31B 134M Sep/2025
Novavax USD 66.95M 34.05M Sep/2024
Pfizer USD 4.08B 894M Dec/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Veracyte USD 51.73M 5.91M Sep/2025